Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;60(10):1410-1412.
doi: 10.1038/s41409-025-02690-3. Epub 2025 Jul 31.

Infections in steroid-refractory chronic graft versus host disease patients treated with ruxolitinib, ibrutinib, or belumosudil

Victoria Stepanyants  1 , Hong Li  2 , Danielle Cenin  3 , Jessi Edwards  3 , Claudio Brunstein  3 , Matt Kalaycio  3 , Ronald Sobecks  3 , Craig S Sauter  4 , Betty K Hamilton  5
Affiliations

Infections in steroid-refractory chronic graft versus host disease patients treated with ruxolitinib, ibrutinib, or belumosudil

Victoria Stepanyants et al. Bone Marrow Transplant. 2025 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors report the following conflicts of interest: Dr. Hamilton reports (ad hoc) advisory boards for Sanofi, Incyte, Maat; research funding from Incyte; adjudication committee with CSL Behring. The remaining authors have no relevant disclosures to report. Ethics approval and consent to participate: This study was approved by the Cleveland Clinic Institutional Review Board, which deemed this study minimal risk research not requiring informed consent. All methods were performed in compliance with the relevant regulations, including the Declaration of Helsinki. No identifiable patient details are presented in this manuscript.

References

    1. Hamilton BK. Updates in chronic graft-versus-host disease. Hematol Am Soc Hematol Educ Program. 2021;2021:648–54. - DOI
    1. Flowers MED, Storer B, Carpenter P, Rezvani AR, Vigorito AC, Campregher PV, et al. Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2008;14:1380–4. - DOI - PubMed - PMC
    1. Garnett C, Apperley JF, Pavlů J. Treatment and management of graft-versus-host disease: improving response and survival. Therapeutic Adv Hematol. 2013;4:366–78. - DOI
    1. DeFilipp Z, Alousi AM, Pidala JA, Carpenter PA, Onstad LE, Arai S, et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood Adv. 2021;5:4278–84. - DOI - PubMed - PMC
    1. FDA Newsroom [Internet]. FDA; 2017 [cited 2023 Nov 9]. FDA approves treatment for chronic graft versus host disease. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-treatme... .

LinkOut - more resources